

**A COMPARISON OF ORALLY ADMINISTERED MISOPROSTOL  
WITH VAGINALLY ADMINISTERED MISOPROSTOL FOR  
CERVICAL RIPENING AND LABOR INDUCTION**

Thesis

*Submitted for fulfillment of Master Degree in Obstetrics and Gynecology*

By

**HANY SAAD AMIN MOHAMED**

*Resident of Obstetrics and Gynecology  
Faculty of Medicine-Cairo University*

**Supervised by**

**POF. DR. MAHER MOHAMED ABDEL WAHAB**

*Professor of Obstetrics & Gynecology  
Faculty of Medicine-Cairo University*

**PROF. DR. ASHRAF ABDEL RAHMAN RAMADAN**

*Professor of Obstetrics & Gynecology  
Faculty of Medicine-Cairo University*

**DR. AHMED MOHAMED ABDEL HAKE**

*Lecturer of Obstetrics & Gynecology  
Faculty of Medicine-Cairo University*

Fuculty of Medicine

Cairo University

2008

## Abstract

**Objectives:** Our purpose was to compare orally administered with vaginally administered misoprostol for cervical ripening and labor induction.

**Patients and Methods:** 40 subjects with medical or obstetrical indications for labor induction and undilated, uneffaced cervixes were randomly assigned to receive orally administered or vaginally administered misoprostol. 50ug of oral misoprostol or 25ug of vaginal misoprostol was given every 4 hrs. If cervical ripening( Bishop score of  $\geq 8$  or cervical dilatation of  $\geq 3$ cm) or active labor didn't occur, repeated doses were given to a maximum of 6 doses or 24 hrs. Thereafter, oxytocin was administered intravenously by a standardized incremental infusion protocol to a maximum of 22mU/min.

**Results:** of the 40 subjects evaluated, 20 received orally administered misoprostol and 20 subjects received vaginally administered misoprostol. fewer orally treated subjects( 3 cases where 2 cases are multigravida and 1 case primigravida) were delivered in 24 hrs of the initiation of induction, in comparison with the vaginally treated group( 16 cases where 9 cases are multigravida and 7 cases are primigravida). The time from induction to delivery in the orally treated group was  $35.5 \pm 12$  hrs (mean and SD) in nulligravida,  $23 \pm 13$  hrs (mean and SD) in multigravida, while in the vaginally treated group was  $21.5 \pm 14$  hrs (mean and SD) in nulligravida,  $19 \pm 10$  hrs (mean and SD) in multigravida. the mean time interval between the induction to initiation of vaginal delivery between the orally treated group  $28.9 \pm 13$  hrs(mean and SD) while in the vaginally treated group  $20 \pm 13$  hrs(mean and SD). the induction to initiation of delivery (vaginal or abdominal) as  $29 \pm 12$  hrs(mean and SD) in the orally treated group,  $21 \pm 12$  hrs(mean and SD) in the vaginally treated group. the average number of doses of misoprostol used for induction as  $3.3 \pm 1.7$ (mean and SD) in the orally treated group while  $2.2 \pm 1.3$ (mean and SD) in the vaginally treated group (  $P = 0.043$ ). Oxytocin augmentation was used in 15 cases in the

orally treated and 12 cases in the vaginally treated group(  $P = 0.500$ ). The number of cases delivered vaginally in the orally treated group 12 cases(60%) while in the vaginally treated group 19 cases(95%). The number of cases delivered by CS in the orally treated group were 8 cases while in the vaginally treated group were 1 case(  $P = 0.023$ ). Chorioamnionitis occurred in 4 cases in oral group, 3 cases in the vaginal group. Uterine tachysystol occurred in 1 case in oral group, 2 cases in the vaginal group. Uterine hypertonus occurred in 1 case in the oral group while no cases reported in the vaginal group. Abnormal FHR pattern reported in 5 cases in the oral group, 6 cases in the vaginal group with no statistical difference between both groups. The neonatal outcome show no statistical difference between both groups.

**Conclusion:** Oral administration of 50ug of misoprostol appears less effective than vaginal administration of 25ug of misoprostol for cervical ripening and labor induction.


**Key words:** Misoprostol, cervical ripening, labor induction.

# Contents

	Page
Introduction .....	1
Aim of work .....	3
Review of literature .....	4
• Cervix:	
▪ Anatomy .....	4
▪ Histology .....	9
▪ Physiology .....	13
▪ Adaptation of cervix to pregnancy.....	14
▪ Adaptation of the cervix during labor.....	17
• Cervical ripening:	
▪ Cervical ripening .....	19
▪ Hormonal control of cervical ripening.....	21
▪ Cervical assessment .....	25
▪ Methods of cervical ripening .....	30
• Misoprostol: .....	38
▪ Chemistry .....	39
▪ Pharmacology .....	39
▪ Pharmacokinetics .....	40
▪ Pharmacodynamics .....	40
▪ Misoprostol biological effects .....	40
▪ Modes of administration .....	41
▪ Clinical guidelines .....	43
Patients and methods .....	45
Results .....	51
Discussion .....	69
Conclusion .....	76
Summary .....	78
References .....	82
Arabic summary .....	

## List of Tables

Table No.	Page
1. Bishop scoring system (1964) .....	25
2. The Burnett scoring system (1966) .....	25
3. Field scoring system (1966) .....	26
4. Friedman scoring system (1967) .....	27
5. Cervical scoring system Calder et al(1977) .....	27
6. Lange scoring system (1982) .....	28
7. Dhall scoring system (1986) .....	28
8. Selection of candidates for induction of labor and cervical ripening .....	30
9. Misoprostol Dosages for Reproductive Health .....	43
10. Selection of candidates for induction of labor and cervical ripening .....	50
11. Intrapartum complications after oral or vaginal administration of misoprostol .....	50
12. The comparison between both treatment groups among the Induction to delivery interval, initiation of vaginal delivery, Initiation of delivery .....	52
13. The comparison between both treatment groups among the average No of doses, Bishop score at induction, Bishop score at redosing .....	55
14. The comparison between both treatment groups among the average No of cases delivered in 12hrs, 24hrs, delivered by CS .....	57
15. The comparison between both treatment groups among the complication during induction by misoprostol .....	60
16. The comparison between both treatment groups with regard to the fetal outcome after induction by misoprostol .....	64



## List of Figures

Figure No.	Page
Fig (1): Vagina. A. Left half of pelvis cut away. B. Vaginal fornix and cervix as viewed through a speculum.....	5
Fig (2): Branches of the anterior trunk of the internal iliac artery .....	6
Fig (3): Uterine and vaginal arteries.....	7
Fig (4): Pelvic lymphatics.....	8
Fig (5): Schematic representation of the factors that may control cervical ripening.....	21
Fig (6): Misoprostol structure.....	38
Fig (7): Safe single doses of vaginal misoprostol for producing uterine contractions at various gestations.....	44
Fig (8): Comparison between the oral group & vaginal group in the mean time of delivery.....	52
Fig (9): Comparison between the oral group & vaginal group in mean time of induction to delivery interval in multigravida.....	53
Fig (10): Comparison between the oral group&vaginal group In the mean time of induction to delivery interval in Primigravida.....	53
Fig (11): Comparison between the oral group & vaginal group in the mean time of initiation of vaginal delivery....	54
Fig (12): Comparison between the oral group & vaginal group in the mean time of initiation of delivery.....	54
Fig (13): show the comparison between oral and vaginal group in the average No of doses, Bishop score at time of induction, and Bishop score before redosing.....	55
Fig (14): Comparison between the oral group & vaginal group in the average number of doses of misoprostol used for induction.....	56
Fig (15): Comparison between the oral group & vaginal group in the Bishop score before redosing.....	56
Fig (16): Comparison between the oral group & vaginal group in the Bishop score at the time of induction .....	57

Fig (17): Comparison between the oral group & vaginal group in the number of cases delivered in 12hrs, 24hrs, by CS.....	58
Fig (18): Comparison between the oral group & vaginal group in the number of cases delivered in 12hrs.....	58
Fig (19): Comparison between the oral group & vaginal group in the number of cases of primigravida delivered in 24 hrs.....	59
Fig (20): Comparison between the oral group & vaginal group in the number of cases of multigravida delivered in 24 hrs.....	59
Fig (21): Comparison between the oral group & vaginal group in the number of cases delivered by CS.....	60
Fig (22): Comparison between the oral group & vaginal group in the complications of misoprostol induction.....	61
Fig (23): Comparison between the oral group & vaginal group in the number of cases affected by chorioamnionitis	61
Fig (24): Comparison between the oral group & vaginal group in the number of cases affected by abnormal FHR pattern.....	62
Fig (25): Comparison between the oral group & vaginal group in the number of cases affected by Hypertonus.....	62
Fig (26): Comparison between the oral group & vaginal group in the number of cases affected by Tachysystole.....	63
Fig (27): Comparison between the oral group & vaginal group in the number of cases receiving oxytocin for induction.....	63
Fig (28): comparison between the oral group & vaginal group in the neonatal outcome.....	64
Fig (29): comparison between the oral group & vaginal group in the neonatal resuscitation.....	65
Fig (30): comparison between the oral group & vaginal group in the number of neonates who are intubated after delivery.....	65



Fig (31): comparison between the oral group & vaginal group in the number of neonates who are needing IPPV after delivery.....	66
Fig (32): comparison between the oral group & vaginal group in the number of neonates who are needing oxygen supplementation after delivery.....	66
Fig (33): comparison between the oral group & vaginal group in the number of neonates with thin meconium.....	67
Fig (34): comparison between the oral group & vaginal group in the number of neonates with thick meconium.....	67
Fig (35): comparison between the oral group & vaginal group in the number of neonates with Apgar score at 1 min < 7.....	68

## List of abbreviations

FHR	Fetal heart rate
GAG	Glucosaminoglycan
IL-6	Interleukin-6
IUFD	Intrauterine fetal death
IUGR	Intrauterine growth retardation
Min	Minutes
hrs	Hours
NO	Nitric Oxide
PGE2	Prostaglandin E2(Dinoproston)
PGF2 $\alpha$	Prostaglandin F2 $\alpha$
PGI <sub>2</sub>	Prostacyclin
RU486	Mifepristone
U.S	United states

## Acknowledgment

I wish to express my deepest and profound thanks to **Prof. Dr. Maher Abdel Wahab**, Professor of Obstetrics and Gynecology, Kasr Al-Aini Hospital, Cairo University, for giving me honor and great privilege of working under his kind supervision, for his continuous encouragement and his fatherly guidance.

I would like to express my endless appreciation to **Prof. Dr. Ashraf Abdel Rahman Rmadan**, Professor of Obstetrics and Gynecology, Kasr Al-Aini Hospital, Cairo University, for his enthusiasm, criticism, continuous support and interest in his work

Special words of thanks are due to **Dr. Ahmed abdel Hake**, Lecturer of Obstetrics and Gynecology, Kasr Al-Aini Hospital, Cairo University, for his great help and support. His participation as well as his encouragement.

## Introduction

There are many indications for term labor inductions, including postterm pregnancy, preeclampsia, diabetes mellitus, oligohydramnios, IUFD, IUGR, abnormal antepartum fetal surveillance results. The immature cervix is the greatest barrier to labor induction. Because oxytocin only affect only the uterine contractions and not the cervical ripening, prostaglandin agents are the first choice for labor induction because they exert a local effect on the cervix, causing effacement and dilatation, and stimulate myometrial contractions, increasing the likelihood of success. Dinoprostone has been the agent of choice of preinduction cervical ripening for several decades and is currently one of the pharmacological agents approved by the U.S Food and Drug administration for this indication. Although widely used, it has two disadvantages: It is expensive, and it require continuous refrigeration .Thus, there is a need for less costly and less temperature-sensitive alternatives. Misoprostol, a synthetic PGE1 analogue, has been proposed as an alternative agent for the preinduction of cervical ripening. Misoprostol was initially used for treatment of peptic ulcer caused by prostaglandin synthetase inhibitors, and was approved by the U.S. Food and Drug Administration for Obstetric use in April 2002.

Although the oral dose of 100 ug was previously advocated as preferred dose by *wing et al*, more recent reports by *Cochrane* review, other review, and forthcoming WHO recommendation have identified 50 ug as the highest dose that should be used. The recommended dose by vaginal route is 25 ug every 4 hrs. however, excessive uterine contractility resulting in fetal distress is a cause for concern. Comparing the oral and vaginal administration of misoprostol, the oral administration is easier and has greater acceptability among women, convenience and lack of invasiveness. Fewer cervical examinations could also reduce the peripartum infection rates. Further, absorption is more rapid and possibly more predictable, with peak serum

concentration after oral administration of 34 min and a half life of 10-40 min. Peak serum concentration for vaginal administration is 60-80 min, and this level is sustained for up to 4 hrs. Oral administration, if proved safe and effective, could potentially reduce overall hospitalization time by permitting administration of the medication in an outpatient setting. Although the direct local effect of vaginal administration on cervical ripening may be advantageous, the shorter half life of oral delivery may be beneficial in the event of uterine hyperstimulation .

## **Aim of work**

A comparison of orally administered Misoprostol with vaginally administered Misoprostol for cervical ripening & induction of labor.

*Review*  
*Of*  
*Literature*